<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01235546</url>
  </required_header>
  <id_info>
    <org_study_id>F090323006</org_study_id>
    <secondary_id>NIH 1R01HD064729-01A1</secondary_id>
    <nct_id>NCT01235546</nct_id>
  </id_info>
  <brief_title>Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection</brief_title>
  <acronym>C/SOAP</acronym>
  <official_title>Cesarean Section Optimal Antibiotic Prophylaxis Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alan Tita</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of North Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mission Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ochsner Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Mississippi Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Cesarean Section Optimal Antibiotic Prophylaxis (C/SOAP) study is a large pragmatic
      multi-center randomized clinical trial designed to evaluate the comparative effectiveness and
      safety of azithromycin-based extended-spectrum antibiotic prophylaxis (azithromycin plus
      standard narrow-spectrum cephalosporin) relative to standard single-agent cephalosporin
      (preferably prior to surgical incision) to prevent post-cesarean infection.

      Hypothesis: Compared to narrow-spectrum prophylaxis (i.e. cefazolin alone, or clindamycin if
      cephalosporin allergy) prior to surgical incision, the addition of extended-spectrum
      prophylaxis (azithromycin + cefazolin) reduces the incidence of post-cesarean infection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants With Endometritis and/or Wound Infection and/or Other Post-cesarean Infections (Occurring Within 6 Weeks of Delivery)</measure>
    <time_frame>Up to 6 weeks after delivery</time_frame>
    <description>Endometritis was defined as the presence of at least two of the following signs with no other recognized cause: fever (temperature of at least 38°C [100.4°F]), abdominal pain, uterine tenderness, or purulent drainage from the uterus. Wound infection was defined as the presence of either superficial or deep incisional surgical-site infection characterized by cellulitis or erythema and induration around the incision or purulent discharge from the incision site with or without fever and included necrotizing fasciitis. Wound hematoma, seroma, or breakdown alone in the absence of the preceding signs did not constitute infection.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Neonatal Morbidities (Listed Below)</measure>
    <time_frame>Up to 3 months after birth</time_frame>
    <description>morbidities include: death, Respiratory Distress Syndrome (RDS), Bronchopulmonary Dysplasia (BPD), Periventricular Leukomalacia (PVL) suspected or proven sepsis, Necrotizing Enterocolitis (NEC) Intraventricular Hemorrhage (IVH) and systemic inflammatory response syndrome</description>
  </other_outcome>
  <other_outcome>
    <measure>Neonatal Intensive Care Unit (NICU) Admission</measure>
    <time_frame>Up to 3 months after birth</time_frame>
    <description>Neonates who are admitted to the NICU due to morbidities diagnosed from birth and up to three months of life. Morbidities as defined in the Neonatal morbidities outcome measure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Neonatal Readmission</measure>
    <time_frame>Up to 3 months after birth</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Maternal Fever</measure>
    <time_frame>Up to 6 weeks after delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Maternal Postpartum Readmission or Unscheduled Visit</measure>
    <time_frame>Up to 6 weeks after delivery</time_frame>
    <description>Maternal postpartum unscheduled visit or readmission to the hospital</description>
  </other_outcome>
  <other_outcome>
    <measure>Maternal Postpartum Antibiotic Use</measure>
    <time_frame>Up to 6 weeks after delivery</time_frame>
    <description>Maternal postpartum use of antibiotics</description>
  </other_outcome>
  <other_outcome>
    <measure>Maternal Serious Adverse Events</measure>
    <time_frame>Up to 6 weeks after delivery</time_frame>
    <description>All maternal serious adverse events</description>
  </other_outcome>
  <other_outcome>
    <measure>Neonatal Serious Adverse Events</measure>
    <time_frame>Up to 3 months after birth</time_frame>
    <description>Composite for all neonatal serious adverse events</description>
  </other_outcome>
  <other_outcome>
    <measure>Infant Pyloric Stenosis</measure>
    <time_frame>up to 3 months after birth</time_frame>
    <description>Any diagnosis of pyloric stenosis based on clinical presentation and radiological and/or surgical confirmation</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2013</enrollment>
  <condition>Endometritis</condition>
  <condition>Wound Infection</condition>
  <condition>Abscess</condition>
  <condition>Surgical Site Infection</condition>
  <arm_group>
    <arm_group_label>Placebo and standard of care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>250 cc normal saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azithromycin and Standard of care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mg Azithromycin in 250 cc normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin and standard of care</intervention_name>
    <description>500 mg in 250 cc normal saline 1 time dose plus standard of care (cephazolin or clindamycin)</description>
    <arm_group_label>Azithromycin and Standard of care</arm_group_label>
    <other_name>Zithromax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo and standard of care</intervention_name>
    <description>250 cc normal saline, plus standard of care (cephazolin or clindamycin)</description>
    <arm_group_label>Placebo and standard of care</arm_group_label>
    <other_name>normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Pregnant Women aged 14 years and over at ≥ 24 weeks' viable gestation who will undergo
        unscheduled/non-elective cesareans with either:

          1. Labor (spontaneous or induced): active labor (ongoing contractions and at least 4cm
             dilated or contractions for at least 4 hours with documented cervical change of ≥1cm
             dilatation or ≥50% effacement), or

          2. Membrane rupture (standardized to duration of at least 4 hours prior to
             randomization).

        Exclusion Criteria:

          -  Patient unwilling or unable to provide consent

          -  Multiple pregnancy

          -  Known azithromycin (or other macrolide) allergy

          -  Vaginal delivery

          -  Elective or scheduled cesarean prior to labor or membrane rupture.

          -  Azithromycin, erythromycin or other macrolide antibiotic use within 7 days of
             enrollment.

          -  Clinical chorioamnionitis or any other active bacterial infection (e.g.
             pyelonephritis, pneumonia, abscess) at time of randomization.

          -  Patient is unable or unlikely to follow-up after delivery (e.g. no prenatal care or a
             non-resident patient)

          -  Fetal demise or major congenital anomaly

          -  Significant liver disease defined as known cirrhosis or elevated transaminases of at
             least 3-fold upper limit of normal

          -  Significant renal disease defined as serum creatinine known to be &gt;2.0 mg/dl or on
             dialysis.

          -  Active congestive heart failure (EF&lt;45%) or pulmonary edema

          -  Active diarrhea at time of delivery

          -  Any patient with significant electrolyte abnormalities such as hypokalemia or
             hypocalcemia

          -  Any patient with structural heart disease or arrhythmias, or taking any medications
             known to prolong the QT interval

          -  Patient currently being treated with efavirenz, nelfinavir or fluconazole
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan TN Tita, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mission Hospital</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-0587</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Tita AT, Rouse DJ, Blackwell S, Saade GR, Spong CY, Andrews WW. Emerging concepts in antibiotic prophylaxis for cesarean delivery: a systematic review. Obstet Gynecol. 2009 Mar;113(3):675-82. doi: 10.1097/AOG.0b013e318197c3b6. Review.</citation>
    <PMID>19300334</PMID>
  </reference>
  <reference>
    <citation>Andrews WW, Hauth JC, Cliver SP, Savage K, Goldenberg RL. Randomized clinical trial of extended spectrum antibiotic prophylaxis with coverage for Ureaplasma urealyticum to reduce post-cesarean delivery endometritis. Obstet Gynecol. 2003 Jun;101(6):1183-9.</citation>
    <PMID>12798523</PMID>
  </reference>
  <reference>
    <citation>Tita AT, Hauth JC, Grimes A, Owen J, Stamm AM, Andrews WW. Decreasing incidence of postcesarean endometritis with extended-spectrum antibiotic prophylaxis. Obstet Gynecol. 2008 Jan;111(1):51-6. doi: 10.1097/01.AOG.0000295868.43851.39.</citation>
    <PMID>18165392</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2010</study_first_submitted>
  <study_first_submitted_qc>November 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2010</study_first_posted>
  <results_first_submitted>March 13, 2017</results_first_submitted>
  <results_first_submitted_qc>June 29, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 28, 2017</results_first_posted>
  <last_update_submitted>June 29, 2017</last_update_submitted>
  <last_update_submitted_qc>June 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Alan Tita</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Pregnancy</keyword>
  <keyword>Cesarean section</keyword>
  <keyword>Antibiotic</keyword>
  <keyword>Infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Surgical Wound Infection</mesh_term>
    <mesh_term>Wound Infection</mesh_term>
    <mesh_term>Endometritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were randomly assigned to receive either azithromycin (at a dose of 500mg in 250 ml of saline, one time dose) or an identical-appearing saline placebo and the standard of care (cephazolin or clindamycin)</recruitment_details>
      <pre_assignment_details>The addition of azithromycin and the standard of care (cephazolin or clindamycin) for antibiotic prophylaxis before cesarean delivery may further reduce the rate of postoperative infection. We evaluated the benefits and safety of azithromycin prophylaxis and the standard of care in women undergoing nonelective cesarean section.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo and Standard of Care</title>
          <description>Placebo: 250 cc normal saline Standard of care (cephazolin or clindamycin)</description>
        </group>
        <group group_id="P2">
          <title>Azithromycin and Standard of Care</title>
          <description>Azithromycin: 500 mg in 250 cc normal saline 1 time dose and standard of care (cephazolin or clindamycin)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="994"/>
                <participants group_id="P2" count="1019"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="992"/>
                <participants group_id="P2" count="1018"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Staff error, medication not administered</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo With Standard Prophylaxis</title>
          <description>Placebo: 250 cc normal saline Standard Prophylaxis: standard cephalosporin prophylaxis</description>
        </group>
        <group group_id="B2">
          <title>Azithromycin (Zithromax) With Standard Prophylaxis</title>
          <description>Azithromycin: 500 mg in 250 cc normal saline 1 time dose Standard Prophylaxis: standard cephalosporin prophylaxis</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="994"/>
            <count group_id="B2" value="1019"/>
            <count group_id="B3" value="2013"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.4" spread="6.5"/>
                    <measurement group_id="B2" value="28.2" spread="6.1"/>
                    <measurement group_id="B3" value="28.3" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="994"/>
                    <measurement group_id="B2" value="1019"/>
                    <measurement group_id="B3" value="2013"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="994"/>
                    <measurement group_id="B2" value="1019"/>
                    <measurement group_id="B3" value="2013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Prevalence</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participants With Endometritis and/or Wound Infection and/or Other Post-cesarean Infections (Occurring Within 6 Weeks of Delivery)</title>
        <description>Endometritis was defined as the presence of at least two of the following signs with no other recognized cause: fever (temperature of at least 38°C [100.4°F]), abdominal pain, uterine tenderness, or purulent drainage from the uterus. Wound infection was defined as the presence of either superficial or deep incisional surgical-site infection characterized by cellulitis or erythema and induration around the incision or purulent discharge from the incision site with or without fever and included necrotizing fasciitis. Wound hematoma, seroma, or breakdown alone in the absence of the preceding signs did not constitute infection.</description>
        <time_frame>Up to 6 weeks after delivery</time_frame>
        <population>The specific characteristics related to the cesarean delivery, including indications for cesarean delivery, receipt of standard prophylaxis, timing of receipt of study medication, and type of surgical skin preparation, were similar in the two groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>250 cc normal saline
Placebo: 250 cc normal saline</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin</title>
            <description>Azithromycin: 500 mg in 250 cc normal saline 1 time dose</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Endometritis and/or Wound Infection and/or Other Post-cesarean Infections (Occurring Within 6 Weeks of Delivery)</title>
          <description>Endometritis was defined as the presence of at least two of the following signs with no other recognized cause: fever (temperature of at least 38°C [100.4°F]), abdominal pain, uterine tenderness, or purulent drainage from the uterus. Wound infection was defined as the presence of either superficial or deep incisional surgical-site infection characterized by cellulitis or erythema and induration around the incision or purulent discharge from the incision site with or without fever and included necrotizing fasciitis. Wound hematoma, seroma, or breakdown alone in the absence of the preceding signs did not constitute infection.</description>
          <population>The specific characteristics related to the cesarean delivery, including indications for cesarean delivery, receipt of standard prophylaxis, timing of receipt of study medication, and type of surgical skin preparation, were similar in the two groups.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="992"/>
                <count group_id="O2" value="1018"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Neonatal Morbidities (Listed Below)</title>
        <description>morbidities include: death, Respiratory Distress Syndrome (RDS), Bronchopulmonary Dysplasia (BPD), Periventricular Leukomalacia (PVL) suspected or proven sepsis, Necrotizing Enterocolitis (NEC) Intraventricular Hemorrhage (IVH) and systemic inflammatory response syndrome</description>
        <time_frame>Up to 3 months after birth</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo and Standard of Care</title>
            <description>Placebo: 250 cc normal saline and standard of care (cefazolin or clindamycin)</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin and Standard of Care</title>
            <description>Azithromycin: 500 mg in 250 cc normal saline 1 time dose and Standard of Care (cefazolin or clindamycin</description>
          </group>
        </group_list>
        <measure>
          <title>Neonatal Morbidities (Listed Below)</title>
          <description>morbidities include: death, Respiratory Distress Syndrome (RDS), Bronchopulmonary Dysplasia (BPD), Periventricular Leukomalacia (PVL) suspected or proven sepsis, Necrotizing Enterocolitis (NEC) Intraventricular Hemorrhage (IVH) and systemic inflammatory response syndrome</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="992"/>
                <count group_id="O2" value="1018"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Neonatal Intensive Care Unit (NICU) Admission</title>
        <description>Neonates who are admitted to the NICU due to morbidities diagnosed from birth and up to three months of life. Morbidities as defined in the Neonatal morbidities outcome measure.</description>
        <time_frame>Up to 3 months after birth</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo and Standard of Care</title>
            <description>250 cc normal saline
Placebo: 250 cc normal saline and Standard of care (cefazolin or clindamycin)</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin and Standard of Care</title>
            <description>Azithromycin: 500 mg in 250 cc normal saline 1 time dose and Standard of care (cefazolin or clindamycin)</description>
          </group>
        </group_list>
        <measure>
          <title>Neonatal Intensive Care Unit (NICU) Admission</title>
          <description>Neonates who are admitted to the NICU due to morbidities diagnosed from birth and up to three months of life. Morbidities as defined in the Neonatal morbidities outcome measure.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="992"/>
                <count group_id="O2" value="1018"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169"/>
                    <measurement group_id="O2" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Neonatal Readmission</title>
        <time_frame>Up to 3 months after birth</time_frame>
        <population>Hospitalization after discharge</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo With Standard Prophylaxis</title>
            <description>Placebo: 250 cc normal saline Standard Prophylaxis: standard cephalosporin prophylaxis</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin (Zithromax) With Standard Prophylaxis</title>
            <description>Azithromycin: 500 mg in 250 cc normal saline 1 time dose Standard Prophylaxis: standard cephalosporin prophylaxis</description>
          </group>
        </group_list>
        <measure>
          <title>Neonatal Readmission</title>
          <population>Hospitalization after discharge</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="992"/>
                <count group_id="O2" value="1018"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Maternal Fever</title>
        <time_frame>Up to 6 weeks after delivery</time_frame>
        <population>Postpartum Fever</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo With Standard Prophylaxis</title>
            <description>Placebo: 250 cc normal saline Standard Prophylaxis: standard cephalosporin prophylaxis</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin (Zithromax) With Standard Prophylaxis</title>
            <description>Azithromycin: 500 mg in 250 cc normal saline 1 time dose Standard Prophylaxis: standard cephalosporin prophylaxis</description>
          </group>
        </group_list>
        <measure>
          <title>Maternal Fever</title>
          <population>Postpartum Fever</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="992"/>
                <count group_id="O2" value="1018"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Maternal Postpartum Readmission or Unscheduled Visit</title>
        <description>Maternal postpartum unscheduled visit or readmission to the hospital</description>
        <time_frame>Up to 6 weeks after delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo and Standard of Care</title>
            <description>Placebo: 250 cc normal saline Standard of care (cefazolin or clindamycin)</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin and Standard of Care</title>
            <description>Azithromycin: 500 mg in 250 cc normal saline 1 time dose Standard of care (cefazolin or clindamycin)</description>
          </group>
        </group_list>
        <measure>
          <title>Maternal Postpartum Readmission or Unscheduled Visit</title>
          <description>Maternal postpartum unscheduled visit or readmission to the hospital</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="992"/>
                <count group_id="O2" value="1018"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123"/>
                    <measurement group_id="O2" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Maternal Postpartum Antibiotic Use</title>
        <description>Maternal postpartum use of antibiotics</description>
        <time_frame>Up to 6 weeks after delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo and Standard of Care</title>
            <description>Placebo: 250 cc normal saline and Standard of care (cefazolin or clindamycin)</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin and Standard of Care</title>
            <description>Azithromycin: 500 mg in 250 cc normal saline 1 time dose and Standard of care (cefazolin or clindamycin)</description>
          </group>
        </group_list>
        <measure>
          <title>Maternal Postpartum Antibiotic Use</title>
          <description>Maternal postpartum use of antibiotics</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="992"/>
                <count group_id="O2" value="1018"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166"/>
                    <measurement group_id="O2" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Maternal Serious Adverse Events</title>
        <description>All maternal serious adverse events</description>
        <time_frame>Up to 6 weeks after delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo and Standard of Care</title>
            <description>Placebo: 250 cc normal saline and Standard of care (cefazolin or clindamycin)</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin and Standard of Care</title>
            <description>Azithromycin: 500 mg in 250 cc normal saline 1 time dose and Standard of care (cefazolin or clindamycin)</description>
          </group>
        </group_list>
        <measure>
          <title>Maternal Serious Adverse Events</title>
          <description>All maternal serious adverse events</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="992"/>
                <count group_id="O2" value="1018"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Neonatal Serious Adverse Events</title>
        <description>Composite for all neonatal serious adverse events</description>
        <time_frame>Up to 3 months after birth</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo and Standard of Care</title>
            <description>Placebo: 250 cc normal saline and Standard of care (cefazolin or clindamycin)</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin and Standard of Care</title>
            <description>Azithromycin: 500 mg in 250 cc normal saline 1 time dose and Standard of care (cefazolin or clindamycin)</description>
          </group>
        </group_list>
        <measure>
          <title>Neonatal Serious Adverse Events</title>
          <description>Composite for all neonatal serious adverse events</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="992"/>
                <count group_id="O2" value="1018"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Infant Pyloric Stenosis</title>
        <description>Any diagnosis of pyloric stenosis based on clinical presentation and radiological and/or surgical confirmation</description>
        <time_frame>up to 3 months after birth</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo and Standard of Care</title>
            <description>Placebo: 250 cc normal saline and Standard of care (cefazolin or clindamycin)</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin and Standard of Care</title>
            <description>Azithromycin: 500 mg in 250 cc normal saline 1 time dose and Standard of care (cefazolin or clindamycin)</description>
          </group>
        </group_list>
        <measure>
          <title>Infant Pyloric Stenosis</title>
          <description>Any diagnosis of pyloric stenosis based on clinical presentation and radiological and/or surgical confirmation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="992"/>
                <count group_id="O2" value="1018"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 6 weeks after delivery</time_frame>
      <desc>Maternal serious adverse events (maternal safety composite outcome) included death, suspected allergic reactions (including anaphylaxis or generalized skin rash), any serious adverse event leading to the discontinuation of a study medication or suspected to be due to the medication, and any other reported serious adverse complication, including pulmonary embolism, admission to an intensive care unit (ICU), and cardiac events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo and Standard of Care</title>
          <description>Placebo: 250 cc normal saline and Standard of care (cefazolin or clindamycin)</description>
        </group>
        <group group_id="E2">
          <title>Azithromycin and Standard of Care</title>
          <description>Azithromycin: 500 mg in 250 cc normal saline and Standard of care (cefazolin or clindamycin)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1018"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Severe allergic reaction</sub_title>
                <description>Allergy</description>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="992"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="1018"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="992"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1018"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ICU admission</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="992"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="1018"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alan Tita, MD</name_or_title>
      <organization>University of Alabama at Birmingham, Maternal &amp; Fetal Medicine</organization>
      <phone>205-934-9616</phone>
      <email>atita@uab.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

